Cargando…

HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP

BACKGROUND: HTLV-1 causes proliferation of clonal populations of infected T cells in vivo, each clone defined by a unique proviral integration site in the host genome. The proviral load is strongly correlated with odds of the inflammatory disease HTLV-1-associated myelopathy/tropical spastic parapar...

Descripción completa

Detalles Bibliográficos
Autores principales: Niederer, Heather A, Laydon, Daniel J, Melamed, Anat, Elemans, Marjet, Asquith, Becca, Matsuoka, Masao, Bangham, Charles RM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192323/
https://www.ncbi.nlm.nih.gov/pubmed/25270762
http://dx.doi.org/10.1186/1743-422X-11-172
_version_ 1782338758946848768
author Niederer, Heather A
Laydon, Daniel J
Melamed, Anat
Elemans, Marjet
Asquith, Becca
Matsuoka, Masao
Bangham, Charles RM
author_facet Niederer, Heather A
Laydon, Daniel J
Melamed, Anat
Elemans, Marjet
Asquith, Becca
Matsuoka, Masao
Bangham, Charles RM
author_sort Niederer, Heather A
collection PubMed
description BACKGROUND: HTLV-1 causes proliferation of clonal populations of infected T cells in vivo, each clone defined by a unique proviral integration site in the host genome. The proviral load is strongly correlated with odds of the inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is evidence that asymptomatic HTLV-1 carriers (ACs) have a more effective CD8 + T cell response, including a higher frequency of HLA class I alleles able to present peptides from a regulatory protein of HTLV-1, HBZ. We have previously shown that specific features of the host genome flanking the proviral integration site favour clone survival and spontaneous expression of the viral transactivator protein Tax in naturally infected PBMCs ex vivo. However, the previous studies were not designed or powered to detect differences in integration site characteristics between ACs and HAM/TSP patients. Here, we tested the hypothesis that the genomic environment of the provirus differs systematically between ACs and HAM/TSP patients, and between individuals with strong or weak HBZ presentation. METHODS: We used our recently described high-throughput protocol to map and quantify integration sites in 95 HAM/TSP patients and 68 ACs from Kagoshima, Japan, and 75 ACs from Kumamoto, Japan. Individuals with 2 or more HLA class I alleles predicted to bind HBZ peptides were classified ‘strong’ HBZ binders; the remainder were classified ‘weak binders’. RESULTS: The abundance of HTLV-1-infected T cell clones in vivo was correlated with proviral integration in genes and in areas with epigenetic marks associated with active regulatory elements. In clones of equivalent abundance, integration sites in genes and active regions were significantly more frequent in ACs than patients with HAM/TSP, irrespective of HBZ binding and proviral load. Integration sites in genes were also more frequent in strong HBZ binders than weak HBZ binders. CONCLUSION: Clonal abundance is correlated with integration in a transcriptionally active genomic region, and these regions may promote cell proliferation. A clone that reaches a given abundance in vivo is more likely to be integrated in a transcriptionally active region in individuals with a more effective anti-HTLV-1 immune response, such those who can present HBZ peptides or those who remain asymptomatic. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1743-422X-11-172) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4192323
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41923232014-10-11 HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP Niederer, Heather A Laydon, Daniel J Melamed, Anat Elemans, Marjet Asquith, Becca Matsuoka, Masao Bangham, Charles RM Virol J Research BACKGROUND: HTLV-1 causes proliferation of clonal populations of infected T cells in vivo, each clone defined by a unique proviral integration site in the host genome. The proviral load is strongly correlated with odds of the inflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). There is evidence that asymptomatic HTLV-1 carriers (ACs) have a more effective CD8 + T cell response, including a higher frequency of HLA class I alleles able to present peptides from a regulatory protein of HTLV-1, HBZ. We have previously shown that specific features of the host genome flanking the proviral integration site favour clone survival and spontaneous expression of the viral transactivator protein Tax in naturally infected PBMCs ex vivo. However, the previous studies were not designed or powered to detect differences in integration site characteristics between ACs and HAM/TSP patients. Here, we tested the hypothesis that the genomic environment of the provirus differs systematically between ACs and HAM/TSP patients, and between individuals with strong or weak HBZ presentation. METHODS: We used our recently described high-throughput protocol to map and quantify integration sites in 95 HAM/TSP patients and 68 ACs from Kagoshima, Japan, and 75 ACs from Kumamoto, Japan. Individuals with 2 or more HLA class I alleles predicted to bind HBZ peptides were classified ‘strong’ HBZ binders; the remainder were classified ‘weak binders’. RESULTS: The abundance of HTLV-1-infected T cell clones in vivo was correlated with proviral integration in genes and in areas with epigenetic marks associated with active regulatory elements. In clones of equivalent abundance, integration sites in genes and active regions were significantly more frequent in ACs than patients with HAM/TSP, irrespective of HBZ binding and proviral load. Integration sites in genes were also more frequent in strong HBZ binders than weak HBZ binders. CONCLUSION: Clonal abundance is correlated with integration in a transcriptionally active genomic region, and these regions may promote cell proliferation. A clone that reaches a given abundance in vivo is more likely to be integrated in a transcriptionally active region in individuals with a more effective anti-HTLV-1 immune response, such those who can present HBZ peptides or those who remain asymptomatic. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1743-422X-11-172) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-30 /pmc/articles/PMC4192323/ /pubmed/25270762 http://dx.doi.org/10.1186/1743-422X-11-172 Text en © Niederer et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Niederer, Heather A
Laydon, Daniel J
Melamed, Anat
Elemans, Marjet
Asquith, Becca
Matsuoka, Masao
Bangham, Charles RM
HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title_full HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title_fullStr HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title_full_unstemmed HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title_short HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP
title_sort htlv-1 proviral integration sites differ between asymptomatic carriers and patients with ham/tsp
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192323/
https://www.ncbi.nlm.nih.gov/pubmed/25270762
http://dx.doi.org/10.1186/1743-422X-11-172
work_keys_str_mv AT niedererheathera htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT laydondanielj htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT melamedanat htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT elemansmarjet htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT asquithbecca htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT matsuokamasao htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp
AT banghamcharlesrm htlv1proviralintegrationsitesdifferbetweenasymptomaticcarriersandpatientswithhamtsp